2nd Quarter - Report

VIATRIS INC. for VIATRIS INC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$640,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 20, 2021 $640,000 Replaced
2nd Quarter - Amendment Oct 15, 2021 $650,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Corporate Tax Policy

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —

Contacted: Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA)

Copyright/Patent/Trademark CPT

Issues related Inter Partes Review (IPR) process for biosimilars and generic drugs Patent Settlements USPTO subject matter eligibility - Section 101

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Budget/Appropriations BUD

Medicaid Rebate provision of the Bipartisan Budget Act of 2015

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC)

Trade (domestic/foreign) TRD

Trade issues related to generic medicines Pharmaceutical supply chain S. 1260 - the U.S. Innovation and Competition Act

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —

Contacted: SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Bills named: S. 1260 (117th)

Financial Institutions/Investments/Securities FIN

Policy related to corporate governance

LobbyistCovered position, as disclosed
DAVID MARIN —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Health Issues HCR

Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Generic drug quality and FDA oversight Part D Formulary Design and Generic Drug Tiering Electronic Labeling of Prescription Drugs H.R. 1319 - American Rescue Plan Act FDA facility inspections Medicare incentives for biosimilar utilization H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act FY2022 Labor, HHS, Education, and Related Agencies Appropriations Bill Generic Drug User Fee Amendments (GDUFA) Complex Generic Drug Approvals H.R. 3 - Lower Drug Costs Now Act H.R. 2846 - Ensuring Access to Lower-Cost Medicines for Seniors Act

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
PETER WALLACE —
ANNE WILSON —

Contacted: Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 4356 (117th), H.R. 1319 (117th), H.R. 3 (117th), H.R. 2846 (117th)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.